Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPZE1 + Tdap vaccine
- Development stage
- Unknown
- Lead developer
- ILiAD Biotechnologies
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intranasal, Intramuscular
01
Overview
BPZE1 + Tdap vaccine is a **combination immunization strategy** comprising two vaccines used together: - **BPZE1**: A live attenuated, genetically modified *Bordetella pertussis* (whooping cough) vaccine delivered intranasally. BPZE1 is designed to induce both mucosal (secretory IgA) and systemic immunity against pertussis, and it expresses the full set of *B. pertussis* antigens. - **Tdap vaccine**: An intramuscular, acellular combination vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis components (e.g., Boostrix). Together, this regimen is under investigation for inducing both strong systemic and mucosal immunity to pertussis (superior to Tdap alone), without reducing tetanus or diphtheria responses, and with a favorable safety profile. Key indication is the **prevention of pertussis (whooping cough)** in children and potentially other groups. BPZE1 is developed by ILiAD Biotechnologies and co-administered with Tdap (commercially available vaccines like Boostrix).
- Brand names
- Boostrix
- Other names
- BPZE1 intranasal + Tdap intramuscularBPZE1 + Boostrix
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on BPZE1 + Tdap vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPZE1 + Tdap vaccine.